Linked e-resources
Details
Table of Contents
Intro; "Resistance to Targeted Anti-Cancer Therapeutics": Aims and Scope; Series Editor Biography; Acknowledgements; Editor's Biography; Preface; Contents; BTK Inhibitors: Focus on Ibrutinib and Similar Agents; Introduction; Ibrutinib Biochemical Structure, PK, PD, Routes and Doses; Ibrutinib: Efficacy and Safety Clinical Data; Resistance to BTK Inhibitors; Clinical Studies on Resistance Mechanisms in CLL; Prognosis After Disease Progression and Transformation in CLL; Resistance Mechanisms in MCL; Clinical Trials and Resistance Mechanisms in Waldenström's Macroglobulinemia
Other BTK InhibitorsConclusion; References; BCL2 Inhibitors: Insights into Resistance; Introduction; BCL2 and Cancer; BH3 Mimetics; ABT-737; Navitoclax; Venetoclax; Biochemistry; Pre-clinical Data; Administration and Pharmacokinetics; Clinical Outcomes; Clinical Effect of Resistance; Molecular Mechanisms of Resistance; Conclusion; References; Proteasome Inhibitors with a Focus on Bortezomib; Introduction; The Ubiquitin Proteasome System; Proteasome Inhibitors: Mechanism of Anti-tumor Effect; Cell Intrinsic Mechanisms of Resistance; Proteasome Subunit Mutations; Efflux Pumps; Autophagy
Plasmacytic DifferentiationProteasome Subunit Expression; BCL-2; Cell Extrinsic Mechanisms of Resistance; Interleukin-6; The Hedgehog Pathway; Overcoming Bortezomib Resistance; Targeting the Immature Plasma Cell; Differentiation Induction; Synergistically Activating the Unfolded Protein Response; BCL-2 Inhibition; Conclusion; References; IMiD: Immunomodulatory Drug Lenalidomide (CC-5013; Revlimid) in the Treatment of Lymphoma: Insights into Clinical Use and Molecular Mechanisms; Introduction; Non-Hodgkin's Lymphoma; Lenalidomide for the Treatment of Lymphoma
Structure and Mechanism of ActionToxicities; Other Insights from Preclinical Models; Clinical Indications and Data; Predictive Markers for Lenalidomide in Patients with Lymphoma; Molecular Mechanisms of Resistance; Future Directions; References; mTOR Inhibitors, with Special Focus on Temsirolimus and Similar Agents; Introduction: Rapamycin and Rapalogs History; The mTOR Pathway and mTOR Inhibitors; Pharmacokinetics of Rapalogs; Toxicity; Pneumonitis; Metabolic Adverse Events; Hematological Toxicities; mTOR Inhibitors Associated Stomatitis (mIAS); Mechanisms of Resistance; Mutations of mTOR
Genetic and Functional HeterogeneityAlternative Proliferation Pathways; Molecular Mechanisms of mTOR Activation in Lymphomas; Summary of Clinical Trials; Temsirolimus; Everolimus; Ridaforolimus; Second Generation mTOR Inhibitors; Summary; References; Inhibitors of the JAK/STAT Pathway, with a Focus on Ruxolitinib and Similar Agents; The JAK/STAT Intracellular Signaling Pathway; Deregulated JAK/STAT Signaling in Lymphomagenesis; Mutations that Alter JAK2 Copy Number but Not Its Coding Sequence; Mutations that Directly Alter the JAK Family Members; Mutations that Target the STAT Family Members
Other BTK InhibitorsConclusion; References; BCL2 Inhibitors: Insights into Resistance; Introduction; BCL2 and Cancer; BH3 Mimetics; ABT-737; Navitoclax; Venetoclax; Biochemistry; Pre-clinical Data; Administration and Pharmacokinetics; Clinical Outcomes; Clinical Effect of Resistance; Molecular Mechanisms of Resistance; Conclusion; References; Proteasome Inhibitors with a Focus on Bortezomib; Introduction; The Ubiquitin Proteasome System; Proteasome Inhibitors: Mechanism of Anti-tumor Effect; Cell Intrinsic Mechanisms of Resistance; Proteasome Subunit Mutations; Efflux Pumps; Autophagy
Plasmacytic DifferentiationProteasome Subunit Expression; BCL-2; Cell Extrinsic Mechanisms of Resistance; Interleukin-6; The Hedgehog Pathway; Overcoming Bortezomib Resistance; Targeting the Immature Plasma Cell; Differentiation Induction; Synergistically Activating the Unfolded Protein Response; BCL-2 Inhibition; Conclusion; References; IMiD: Immunomodulatory Drug Lenalidomide (CC-5013; Revlimid) in the Treatment of Lymphoma: Insights into Clinical Use and Molecular Mechanisms; Introduction; Non-Hodgkin's Lymphoma; Lenalidomide for the Treatment of Lymphoma
Structure and Mechanism of ActionToxicities; Other Insights from Preclinical Models; Clinical Indications and Data; Predictive Markers for Lenalidomide in Patients with Lymphoma; Molecular Mechanisms of Resistance; Future Directions; References; mTOR Inhibitors, with Special Focus on Temsirolimus and Similar Agents; Introduction: Rapamycin and Rapalogs History; The mTOR Pathway and mTOR Inhibitors; Pharmacokinetics of Rapalogs; Toxicity; Pneumonitis; Metabolic Adverse Events; Hematological Toxicities; mTOR Inhibitors Associated Stomatitis (mIAS); Mechanisms of Resistance; Mutations of mTOR
Genetic and Functional HeterogeneityAlternative Proliferation Pathways; Molecular Mechanisms of mTOR Activation in Lymphomas; Summary of Clinical Trials; Temsirolimus; Everolimus; Ridaforolimus; Second Generation mTOR Inhibitors; Summary; References; Inhibitors of the JAK/STAT Pathway, with a Focus on Ruxolitinib and Similar Agents; The JAK/STAT Intracellular Signaling Pathway; Deregulated JAK/STAT Signaling in Lymphomagenesis; Mutations that Alter JAK2 Copy Number but Not Its Coding Sequence; Mutations that Directly Alter the JAK Family Members; Mutations that Target the STAT Family Members